100 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA
Material Contracts, Unregistered Sales of Equity Securities, Reg. FD
Investor Presentation
Separation Agreement with Dr. Qing Zuraw; Chief Development Officer Departs
Announces $150 Million Private Placement
Stock Option Repricing Approved by Vor Biopharma Board on December 5, 2025
Vor Biopharma Inc. Announces $93.7 Million Equity Offering
Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
FY 2025
Q3
Q2
Q1
FY 2024
Q2 amended
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report